ClinicalTrials.gg
RecruitingNCT05987631Updated Aug 14, 2023

Predictors of Weight Loss and Metabolic Health After Bariatric Surgery

An observational study in Obesity, Morbid, Insulin Sensitivity and Bariatric Surgery Candidate, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Obesity, Morbid with a site in Netherlands — 2 open to participants now, 7 under way, none of them phase 3. Obesity, Morbid · Netherlands.

Started
2023
with 2 others
Observational
7 of 31
1 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 31 studies in Obesity, Morbid with a site in Netherlands, this one is one of 3 that started in 2023, is one of 7 observational ones, and was the 31st registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

2 of the 31 studies in Obesity, Morbid with a site in Netherlands are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Obesity, Morbid with a site in Netherlands, or all of them as a file.
02

Study summary

In this prospective study the investigators aim to identify preoperative predictors of improvement of metabolic health and weight loss after bariatric surgery focusing on inflammation, insulin sensitivity (in a subgroup of patients), glucoregulatory determinants, psychological traits, feeding behavior characteristics and cardiorespiratory fitness

Read the detailed description

Obesity is the result of a complex interplay between genetic and epigenetic predisposition, environment, physical activity, nutrition and psychology. It is a debilitating disorder and a risk factor for the development of metabolic disorders such as dyslipidaemia, hypertension and hyperglycaemia as well as certain cancers. Bariatric surgery has proven to be the most effective treatment for morbid obesity with established long-term results of weight loss, remission of comorbid conditions and the improvement of Quality of Life (QoL). However, variability in these results after bariatric surgery is well known. Identifying preoperative predictors of postoperative weight loss and metabolic health is of clinical priority. Predictors could help further improve the efficacy of care for obesity by tailoring treatment to the individual, based on their predicted response and therefore optimize outcome after bariatric surgery.

03

Conditions studied

  • Obesity, Morbid
  • Insulin Sensitivity
  • Bariatric Surgery Candidate
  • Feeding Behavior

Keywords

  • Obesity
  • Bariatric Surgery
  • Metabolic health
  • Weight loss
  • Predictors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients of the Nederlandse Obesitas Kliniek (Dutch Obesity Clinic).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide
  • Patient is ≥ 18 and ≤ 75 years old
  • ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
  • Scheduled for primary bariatric procedure: Roux-en-Y gastric bypass (RYGB) or Sleeve Gastrectomy (SG)
  • Stable weight 3 months prior to inclusion weight (\<10% change in body weight for 3 months prior to assessments)

In order to be eligible to participate in the subgroup of this study, we will use the following inclusion criteria:

  • Ability to provide informed consent
  • Patient is ≥ 18 and ≤ 75 years old
  • BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
  • Patients scheduled for RYGB
  • Patients who are insulin resistant (impaired fasting glucose (> 5.6 mmol/L) or fasting insulin > 74 pmol/L)
  • women (to prevent bias due to the effect of sex hormones on insulin sensitivity)

Exclusion criteria

Exclusion Criteria:

  • Any actual medical condition except for obesity related health issues or well treated hypothyroidism
  • Pregnancy anticipated in the first two years following surgery

A potential subject who meet the following criteria will be excluded from participation in the subgroup of this study:

  • Coagulation disorders and/or use anticoagulants
  • Use of any medication except for statins, antihypertensives (except for Angiotensine converting enzyme (ACE)- or angiotensin receptor blockers) and thyroid hormone
  • Diabetes mellitus type 2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Predictors of improvement in metabolic health - insulin sensitivity

    HOMA-IR

    Time frame: Baseline up to 5 years after surgery

  2. Predictors of improvement in metabolic health - level of glucose control

    HbA1C (mmol/mol)

    Time frame: Baseline up to 5 years after surgery

  3. Predictors of improvement in metabolic health - glucose

    Fasting glucose (mmol/L)

    Time frame: Baseline up to 5 years after surgery

  4. Predictors of improvement in metabolic health - insulin

    Insulin (pmol/L)

    Time frame: Baseline up to 5 years after surgery

  5. Predictors of improvement in metabolic health - lipid profile

    Lipids (mmol/L)

    Time frame: Baseline up to 5 years after surgery

  6. Predictors of improvement in metabolic health - biomarker inflammation

    CRP (mg/L)

    Time frame: Baseline up to 5 years after surgery

  7. Predictors of improvement in metabolic health

    Genetic variants using GWAS analysis

    Time frame: Baseline up to 5 years after surgery

  8. Predictors of weight loss

    Genetic variants using GWAS analysis

    Time frame: Baseline up to 5 years after surgery

Secondary outcomes

  1. Psychological factors - depression

    Patient-Reported Outcomes Measurement Information System Depression (PROMIS-D: validated questionnaire for bariatric surgery. PROMIS-D: range in score from 8 to 40, higher scores indicating greater severity of depression

    Time frame: Baseline up to 5 years after surgery

  2. Psychological factors - anxiety

    Patient-Reported Outcomes Measurement Information System Anxiety (PROMIS-A): validated questionnaire for bariatric surgery. PROMIS-A: range in score from 7 to 35, higher scores indicating greater severity of anxiety.

    Time frame: Baseline up to 5 years after surgery

  3. Psychological factors - impulsivity

    Measurements of impulsiveness Barret Impulsiveness Scale (BIS): validated questionnaire to assess level of impulsivity BIS-11: The total scores can range from 30 to 120. Higher scores on the BIS reflect higher levels of impulsiveness.

    Time frame: Baseline up to 5 years after surgery

  4. Psychological factors - impulsivity

    Measurements of impulsiveness Iowa Gambling Task: validated task to study impulsive behaviour Iowa gambling task: The net score is calculated by subtracting the number of disadvantageous selections from the advantageous selections. A positive net score indicates better performance

    Time frame: Baseline up to 5 years after surgery

  5. Predictors of weight loss - food addiction

    Food addiction scale (YFAS 2.0): validated questionnaire to assess food addiction. YFAS 2.0 includes two scoring methods, a continuous symptom count and a diagnosis of food addiction. Continious symptom count ranges from zero to eleven, Diagnosis of food addiction: no food addiction (0-1 symptoms), a mild food addicition (2-3 symptoms), a moderate food addiction (4-5 symptoms), or a severe food addiction (\>6 symptoms).

    Time frame: Baseline up to 5 years after surgery

  6. Predictors of weight loss - eating behaviour

    Dutch Eating Behaviour Questionnaire (DEBQ): validated questionnaire to assess eating behaviour. DEBQ consists of 33 items.Items on the DEBQ range from 1 (never) to 5 (very often), with higher scores indicating greater endorsement of the eating behavior.

    Time frame: Baseline up to 5 years after surgery

  7. Predictors of weight loss - Quality of Life

    Selfesteem scale of Impact of Weight on Quality of Life - lite (IWQOL-lite): validated questionnaire after weight loss interventions. The self-esteem scale consists of 7 items. Each item is rated on a 5-point scale. Higher scores represent better quality of life.

    Time frame: Baseline up to 5 years after surgery

  8. Predictors of weight loss - Quality of Life

    OBESI-Q (Obesity): validated questionnaire for reporting Health Related Quality of Life. Outcome is expressed on a 100 point scale, a higher score is higher quality of life, with the exception of item "Excess skin".

    Time frame: Baseline up to 5 years after surgery

  9. Predictors of weight loss - Quality of Life

    EuroQuality of Life (EQ-5D): validated questionnaire for reporting Quality of Life after bariatric surgery. Each item is rated on a 5-point scale. Higher scores represent lower reported quality of life.

    Time frame: Baseline up to 5 years after surgery

  10. Predictors of weight loss - Impulsivity

    Measurements of impulsiveness Barret Impulsiveness Scale (BIS): validated questionnaire to assess level of impulsivity BIS-11: The total scores can range from 30 to 120. Higher scores on the BIS reflect higher levels of impulsiveness.

    Time frame: Baseline up to 5 years after surgery

  11. Predictors of weight loss - Impulsivity

    Measurements of impulsiveness Iowa Gambling Task: validated task to study impulsive behaviour Iowa gambling task: The net score is calculated by subtracting the number of disadvantageous selections from the advantageous selections. A positive net score indicates better performance

    Time frame: Baseline up to 5 years after surgery

  12. Predictors of weight loss - Physical activity

    Short Questionnaire to Assess Health Enhancing Physical Activity (SQUASH): validated questionnaire to assess physical activity. The SQUASH measures the frequency, duration and intensity of 5 different physical activities: commuting (traveling to and from work/study), housekeeping , activities at work, leisure time, and sports. A higher score = more time spend on physical activities.

    Time frame: Baseline up to 5 years after surgery

  13. Sexual dimorphism in weight loss

    Males versus females regarding weight loss (kg) and percentage of total weight loss

    Time frame: Baseline up to 5 years after surgery

  14. Sexual dimorphism in restoration of metabolic health - insulin sensitivity

    Males versus females regarding insulin sensitivity (HOMA-IR) and measurements of glucose and insuline

    Time frame: Baseline up to 5 years after surgery

  15. Sexual dimorphism in restoration of metabolic health - improvement of diabetes

    Males versus females regarding HbA1c values and diabetic drug use

    Time frame: Baseline up to 5 years after surgery

  16. Sexual dimorphism in restoration of metabolic health - lipid

    Males versus females regarding lipids (mmol/L) and lipid-lowering agents use

    Time frame: Baseline up to 5 years after surgery

  17. Sexual dimorphism in restoration of metabolic health - hypertension

    Males versus females regarding blood pressure (mmHg) and anithypertensive medication use

    Time frame: Baseline up to 5 years after surgery

  18. Peripheral insulin sensitivity

    In a subset of 40 patients insulin sensitivity will be assessed using hyperinsulinemic euglycemic clamps, and adipose tissue and skeletal muscle biopsies will be taken to assess insulin signalling (expression of mRNA and phosphorylated proteins)

    Time frame: Before and 3 and 18 months after bariatric surgery

07

Study locations

1 of 3 sites recruiting
  • Nederlandse Obesitas Kliniek Nieuwegein
    Nieuwegein, Utrecht 3431HK, Netherlands
    Not yet recruiting
  • Nederlandse Obesitas Kliniek Den Haag
    Den Haag, Zuid-Holland 2591XR, Netherlands
    Recruiting
  • Nederlandse Obesitas Kliniek Gouda
    Gouda, Zuid-Holland 2803PW, Netherlands
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2024, 19 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 19 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2023
First posted
Aug 14, 2023
StartActual
Jan 19, 2023
Primary completionEst.
Aug 31, 2024
CompletionEst.
Aug 31, 2027
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05987631
Collaborators
Obesitas Kliniek B.V., Radboud University Medical Center
Responsible party
Prof. Dr. Mireille JM Serlie (Prof. Dr. Mireille JM Serlie, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Aug 14, 2023
Start date
Jan 19, 2023
Primary completion
Aug 31, 2024 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 14, 2023

Study contacts

Rieneke van der Meer, Drs.
Contact
r.vandermeer1@amsterdamumc.nl
+31703204703
Lianda CH Luiijpers, Drs.
Contact
lianda.luijpers@radboudumc.nl
Mireille JM Serlie, Prof. Dr.
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Valerie M Monpellier, Dr.
principal investigator · Obesitas Nederland B.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion